McKechnie Duncan 4

What Happened

• Duncan McKechnie, EVP and Chief Commercial Officer of Vertex Pharmaceuticals (VRTX), sold 2,437 shares in an open-market transaction on 2026-03-04. The shares were disposed at $475.30 per share, generating approximately $1,158,306 in proceeds. The transaction is reported as a sale (code S).

Key Details

• Transaction date and price: 2026-03-04, 2,437 shares @ $475.30 each.
• Total proceeds: about $1,158,306.
• Footnote: The sale was made pursuant to Mr. McKechnie’s company-approved Rule 10b5-1 trading plan entered on 2025-11-25.
• Filing: Form 4 was filed 2026-03-06 (covers the 2026-03-04 transaction); this appears to be a timely filing.
• Shares owned after the transaction: not disclosed in the provided data.

Context

• Sales under 10b5-1 plans are pre-scheduled transactions and are commonly used by insiders to sell shares without contemporaneous trading decisions; they are often considered routine rather than a direct signal of changed sentiment. As a sale, this is less informative than a purchase when evaluating insider conviction.